About this trial

The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.

Eligibility criteria

Qualifiers

Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg

Individual has a baseline office diastolic blood pressure ≥ 90 mmHg

Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements)

Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline

Disqualifiers

Individual lacks appropriate renal artery anatomy

Individual has undergone prior renal denervation

Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement

Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea

Trial design

Treatments tested in this trial

  • Symplicity Spyral™ multi-electrode renal denervation system

Treatment groups

130 Participants
are divided into 1 treatment group

Locations

21
Australia
The Alfred Hospital Melbourne Australia
Royal Perth Hospital Perth Australia
Belgium
CHC MontLégia4000, LiègeLiège, Belgium
Ziekenhuis Oost Limburg3600, GenkLimburg, Belgium

Sponsors and collaborators

Medtronic Vascular

Lead sponsor